NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development of novel treatments for gastrointestinal (GI) diseases and disorders, today reported its financial results and business update for the three and six months ended June 30, 2015.
“This has been the most successful period in our company’s history, beginning with the excellent results we achieved in our first and second phase 3 trials with plecanatide for CIC”
Help employers find you! Check out all the jobs and post your resume.
